- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 9, Issue 13, 2002
Current Medicinal Chemistry - Volume 9, Issue 13, 2002
Volume 9, Issue 13, 2002
-
-
Thrombin Receptor Antagonists, Recent Advances in PAR-1 Antagonist Development
Authors: M. Anderluh and M. DolencThe receptor for the serine protease thrombin, the protease-activated receptor-1 (PAR-1), has been recently characterized. Its key roles in thrombin-stimulated human platelet activation, vascular endothelial and smooth muscle proliferation, inflammatory responses and neurodegeneration suggest receptor involvement in various disorders such as arterial thrombosis, atherosclerosis, restenosis, inflamma Read More
-
-
-
The Application of Microwave Irradiation as New Convenient Synthetic Procedure in Drug Discovery
Authors: V. Santagada, E. Perissutti and G. CaliendoHeterocyclic compounds hold a special place among pharmaceutically important natural and synthetic materials. The remarkable ability of heterocyclic nuclei to serve both as biomimetics and reactive pharmacophores has largely contributed to their unique value as traditional key elements of numerous drugs.In both lead identification and lead optimization processes there is an acute need for new organic small m Read More
-
-
-
Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents
Authors: L. Tentori and G. GrazianiAmong methylating agents of clinical interest, temozolomide is a novel antitumor compound that has raised particular interest due to its acceptable safety profile and activity against tumors poorly responsive to conventional chemotherapy, such as malignant glioma and metastatic melanoma. Moreover, the drug has recently shown promising antitumor activity in a patient affected by primary brain lymphoma and is currently un Read More
-
-
-
Arylpiperazines with Affinity Toward a1-Adrenergic Receptors
Authors: F. Manetti, F. Corelli, G. Strappaghetti and M. BottaIn the last years, α1 adrenoceptors (α1-AR) have been the subject of intense research, in part because receptor-binding studies and molecular biology have opened up new aspects of understanding but also because of the potential to find new drugs possibly acting toward pathophysiological processes where α1-AR are involved, such as benign prostatic hyperplasia (BPH) or hypertension. At present, arylpiperazines represent Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
